SEC Form SC 13G filed by MoonLake Immunotherapeutics

2/9/24 9:28:31 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MLTX alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 MOONLAKE IMMUNOTHERAPEUTICS CLASS A COMMON STOCK Cusip #61559X104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #61559X104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,845,079 Item 6: 0 Item 7: 3,847,677 Item 8: 0 Item 9: 3,847,677 Item 11: 6.419% Item 12: HC Cusip #61559X104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 3,847,677 Item 8: 0 Item 9: 3,847,677 Item 11: 6.419% Item 12: IN Item 1(a). Name of Issuer: MOONLAKE IMMUNOTHERAPEUTICS Item 1(b). Address of Issuer's Principal Executive Offices: DORFSTRASSE 29 ZUG, 6300 Switzerland Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: 61559X104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 3,847,677 (b) Percent of Class: 6.419% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 3,847,677 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of MOONLAKE IMMUNOTHERAPEUTICS. No one other person's interest in the CLASS A COMMON STOCK of MOONLAKE IMMUNOTHERAPEUTICS is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of MOONLAKE IMMUNOTHERAPEUTICS at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $MLTX alert in real time by email

Recent Analyst Ratings for

$MLTX

Date	Price Target	Rating	Analyst
8/26/2024		Outperform → Peer Perform	Wolfe Research
6/25/2024	$104.00	Outperform	Oppenheimer
4/2/2024	$62.00	Neutral	Goldman
2/15/2024	$77.00	Outperform	Wolfe Research
12/8/2023	$72.00	Buy	Citigroup
11/2/2023	$74.00	Buy	Stifel
9/14/2023		Buy → Neutral	Bryan Garnier
8/31/2023	$76.00	Buy	Needham

More analyst ratings

SEC Form SC 13G filed by MoonLake Immunotherapeutics

Chat with this insight

Recent Analyst Ratings for $MLTX

$MLTX Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

Oppenheimer Initiates Coverage On MoonLake with Outperform Rating, Announces Price Target of $104

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

$MLTX SEC Filings

MoonLake Immunotherapeutics filed SEC Form 8-K: Regulation FD Disclosure

SEC Form 10-Q filed by MoonLake Immunotherapeutics

MoonLake Immunotherapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$MLTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by MoonLake Immunotherapeutics

SEC Form SC 13D/A filed by MoonLake Immunotherapeutics (Amendment)

SEC Form SC 13G/A filed by MoonLake Immunotherapeutics (Amendment)

$MLTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Bvf Partners L P/Il sold $100,003,200 worth of Class A Ordinary Shares (2,000,000 units at $50.00) (SEC Form 4)

Director Sturge Simon sold $9,186,120 worth of Class A ordinary shares (171,000 units at $53.72), decreasing direct ownership by 50% to 171,980 units (SEC Form 4)

SEC Form 4 filed by Director Bvf Partners L P/Il

$MLTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chen Bihua bought $3,524,297 worth of Class A Ordinary Shares (58,839 units at $59.90) (SEC Form 4)

Chen Bihua bought $16,800,343 worth of Class A Ordinary Shares (293,212 units at $57.30) (SEC Form 4)

$MLTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

MoonLake Immunotherapeutics downgraded by Wolfe Research

Oppenheimer initiated coverage on MoonLake Immunotherapeutics with a new price target

Goldman initiated coverage on MoonLake Immunotherapeutics with a new price target

$MLTX Financials

Live finance-specific insights

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

$MLTX Press Releases

Fastest customizable press release news feed in the world

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

Recent Analyst Ratings for
$MLTX

$MLTX
Market Insights

$MLTX
SEC Filings

$MLTX
Large Ownership Changes

$MLTX
Insider Trading

$MLTX
Insider Purchases

$MLTX
Analyst Ratings

$MLTX
Financials

$MLTX
Press Releases